Last reviewed · How we verify
Capecitabine, 5-fluorouracil prodrug; oral — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Capecitabine, 5-fluorouracil prodrug; oral (Capecitabine, 5-fluorouracil prodrug; oral) — Array Biopharma, now a wholly owned subsidiary of Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Capecitabine, 5-fluorouracil prodrug; oral TARGET | Capecitabine, 5-fluorouracil prodrug; oral | Array Biopharma, now a wholly owned subsidiary of Pfizer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Capecitabine, 5-fluorouracil prodrug; oral CI watch — RSS
- Capecitabine, 5-fluorouracil prodrug; oral CI watch — Atom
- Capecitabine, 5-fluorouracil prodrug; oral CI watch — JSON
- Capecitabine, 5-fluorouracil prodrug; oral alone — RSS
Cite this brief
Drug Landscape (2026). Capecitabine, 5-fluorouracil prodrug; oral — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-5-fluorouracil-prodrug-oral. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab